Ameristat Pharmaceuticals, Inc.   

Dacogen - dacogen@aipharma.com

 

INDICATIONS AND USAGE
Dacogen is a nucleoside metabolic inhibitor indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate- 2, and high-risk International Prognostic Scoring System groups. (1)

Learn more about Dacogen at www.dacogen.com